$70.41
0.28[0.40%]
At close: Apr 23
$70.41
0[0.00%]
After Hours: 7:35PM EDT
AstraZeneca
(NASDAQ:AZN)Latest News for AstraZeneca Stock (NASDAQ:AZN)
AstraZeneca Stock (NASDAQ: AZN)
Categories: All
Monday, April 22, 2024
Sunday, April 21, 2024
Friday, April 19, 2024
Wednesday, April 17, 2024
Tuesday, April 16, 2024
- Deutsche Bank Upgrades AstraZeneca to HoldBenzinga Newsdesk - Apr 16, 2024, 2:17PM
- AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data ShowsVandana Singh - Apr 16, 2024, 8:53AM
- AstraZeneca's Imfinzi Plus Chemotherapy Doubled Overall Survival Rate At Three Years For Patients With Advanced Biliary Tract Cancer In TOPAZ-1 Phase 3 TrialBenzinga Newsdesk - Apr 16, 2024, 5:22AM
Friday, April 12, 2024
Thursday, April 11, 2024
- AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package BoostVandana Singh - Apr 11, 2024, 9:04AM
- AstraZeneca shares are trading higher following FDA approval of FASENRA. Additionally, the company raised its 2024 dividend by 7%.Benzinga Newsdesk - Apr 11, 2024, 8:50AM
- FDA Approves AstraZeneca's Fasenra (Benralizumab) For Add-on Maintenance Treatment For Patients With Severe Asthma Aged 6 To 11 With An Eosinophilic PhenotypeBenzinga Newsdesk - Apr 11, 2024, 7:02AM
- Earlier Astrazeneca Announced Increase In 2024 Dividend By 7% To $3.10/ShareCharles Gross - Apr 11, 2024, 5:17AM
Monday, April 08, 2024
Sunday, April 07, 2024
Friday, April 05, 2024
- FDA Grants Accelerated Approval To ENHERTU For Unresectable Or Metastatic HER2-Positive Solid TumorsBenzinga Newsdesk - Apr 5, 2024, 3:30PM
- New Hope for Aggressive Lung Cancer: AstraZeneca's Imfinzi Shows Promising Results in Phase 3 TrialVandana Singh - Apr 5, 2024, 10:19AM
- US Labor Market Heats Up In March: Payrolls Grow By 303,000, Highest In 10 Months, Dampen June Rate Cut Hopes (UPDATED)Piero Cingari - Apr 5, 2024, 9:18AM
- AstraZeneca Says Imfinzi Significantly Improved Overall Survival And Progression-free Survival For Patients With Limited-Stage Small Cell Lung Cancer In ADRIATIC Phase 3 TrialBenzinga Newsdesk - Apr 5, 2024, 6:51AM
Wednesday, April 03, 2024
Tuesday, April 02, 2024
- AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss RaceVandana Singh - Apr 2, 2024, 2:54PM
- Daiichi Sankyo And AstraZeneca's Datopotamab Deruxtecan Moves Forward In The Fight Against Metastatic Breast Cancer With U.S. BLA AcceptanceBenzinga Newsdesk - Apr 2, 2024, 2:18AM
Wednesday, March 27, 2024
Monday, March 25, 2024
Thursday, March 21, 2024
- AstraZeneca Says Saphnelo Shows Higher Rates Of Remission In Patients With Systemic Lupus Erythematosus Vs Standard Therapy Alone Over 4-Year PeriodBenzinga Newsdesk - Mar 21, 2024, 3:49PM
- EXCLUSIVE: 2024 Witnesses Increase In Biotech Initial Public OfferingsAbbey Higginbotham - Mar 21, 2024, 3:04PM
- After Failed Prostate Cancer Study Merck's Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer StudyVandana Singh - Mar 21, 2024, 2:46PM
- Tagrisso With The Addition Of Chemotherapy Showed Favourable Trend In Overall Survival In EGFR-Mutated Advanced Lung Cancer With Further Follow Up In FLAURA2 Phase III TrialBenzinga Newsdesk - Mar 21, 2024, 10:16AM
- Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per MonthVandana Singh - Mar 21, 2024, 7:17AM
Tuesday, March 19, 2024
- AstraZeneca Files For Debt Shelf; Size Not DisclosedBenzinga Newsdesk - Mar 19, 2024, 5:00PM
- Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine PlatformVandana Singh - Mar 19, 2024, 2:16PM
- AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer TreatmentsVandana Singh - Mar 19, 2024, 7:26AM
- Fusion Pharmaceuticals to be Acquired by AstraZeneca for $2B Plus Milestones in Oncology BreakthroughBenzinga Newsdesk - Mar 19, 2024, 3:06AM
Monday, March 18, 2024
- Watching Puma Biotechnology; Traders Circulate Rumor, "Puma Has Been Dismissed As A Plaintiff In Its Case Against AstraZeneca Alleging That Tagrisso Infringes Its Patents Citing Lack Of Standing"Benzinga Newsdesk - Mar 18, 2024, 2:07PM
- AstraZeneca Says Lynparza/Imfinzi Combo Shows Strong Clinical Benefit Vs. Chemotherapy In Endometrial CancerVandana Singh - Mar 18, 2024, 10:25AM
- GRAIL Announces Novel Risk Classification Test On Its Methylation Platform To Be Used In Lung Cancer StudyHappy Mohamed - Mar 18, 2024, 9:01AM
- Lynparza And Imfinzi Demonstrated Clinical Benefit And Median Duration Of Response Vs. Chemotherapy In Patients With pMMR Advanced Or Recurrent Endometrial CancerBenzinga Newsdesk - Mar 18, 2024, 8:18AM
- AstraZeneca Caps Patient Out-Of-Pocket Costs At $35 Per Month For Its US Inhaled Respiratory PortfolioBenzinga Newsdesk - Mar 18, 2024, 7:02AM
Thursday, March 14, 2024
- Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech ExodusVandana Singh - Mar 14, 2024, 4:03PM
- AstraZeneca Beefs Up Its Endocrine Disease Pipeline With Amolyt Pharma Deal Worth $1.05BVandana Singh - Mar 14, 2024, 12:25PM
- AstraZeneca To Acquire Amolyt For Up To $1.05BCharles Gross - Mar 14, 2024, 5:33AM
Wednesday, March 13, 2024
Monday, March 11, 2024
- Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'Piero Cingari - Mar 11, 2024, 10:38AM
- On March 8, Insmed Received Notice Of Exercise By Astrazeneca AB Of Its Second And Final Option Under License Agreement, Dated Oct 4, 2016Benzinga Newsdesk - Mar 11, 2024, 9:35AM